This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2026 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.86% per year. These returns cover a period from January 1, 1988 through September 7, 2026. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View the Zacks #1 Rank List
Zacks News
Healthcare and Value: 2 ETFs to Watch for Outsized Volume
by Sweta Killa
IHF and SPYV saw massive trading volumes on Friday.
Healthcare ETFs: Winners & Losers in the Light of U.S. Election
by Sanghamitra Saha
The coronavirus vaccine development effort has put the spotlight on the U.S. healthcare sector in recent months.
UnitedHealth Q3 Solid Result Put Healthcare ETFs in Focus
by Sweta Killa
UnitedHealth reported better-than-expected third-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues. It also lifted its full year outlook.
Trump vs. Biden First Presidential Debate: ETFs in Focus
by Sweta Killa
After months of campaign, President Donald Trump and Democratic nominee Joe Biden will come face-to-face on debate stage on Sep 30 in Cleveland.
Key ETF Areas to Track as Biden Victory Looks Quite Likely
by Sanghamitra Saha
According to a poll, Democratic presidential candidate Joe Biden now has a 71% chance of winning the White House.
S&P 500 Near Record Close: 3 Winning Sectors & ETFs
by Sanghamitra Saha
S&P 500 got charged up on Aug 12 on vaccine and further stimulus hopes as well as better-than-feared second-quarter earnings.
ETFs Set to Surge on Virtual Healthcare Deal
by Sweta Killa
The ongoing boom in online care and consultations has led to merger & acquisition activity in the telehealth services space.
UnitedHealth Beats: Healthcare ETFs in Focus
by Sweta Killa
UnitedHealth Group reported stronger-than-expected second-quarter 2020 results wherein it breezed past the Zacks Consensus Estimate on both earnings and revenues.
ETFs to Play New Trends Triggered by COVID-19
by Sweta Killa
The pandemic has resulted in new trends that will continue at least this year.
Healthcare & Biotech ETFs Digest GILD's Failure News: 5 Winners
by Sanghamitra Saha
Biotech and healthcare ETFs were pretty stable on Apr 23 despite the news that Gilead's Remdesivir failed to improve Covid-19 patients' condition.